FindTrial
Sign In

POF

DRUG8 trials

Sponsors

Fujian Cancer Hospital

Conditions

Advanced CancerAdvanced Gastric AdenocarcinomaGastric AdenocarcinomaGastric CancerGastric Cancer Stage IIIMalignant Neoplasm of Stomach Stage IV

Phase 1

Phase I Study of the Combination of Apatinib and POF
NCT03244774
Fujian Cancer HospitalGastric Adenocarcinoma
Start: 2018-01-01End: 2019-06-30Target: 18Updated: 2018-01-26

Phase 2

POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC
CompletedNCT02845908
Fujian Cancer HospitalMalignant Neoplasm of Stomach Stage IV
Start: 2015-11-30End: 2020-05-31Updated: 2021-04-23
Study of the Combination of Apatinib and POF
NCT03707639
Fujian Cancer HospitalGastric Adenocarcinoma
Start: 2018-11-30End: 2020-11-30Target: 26Updated: 2018-10-16
Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma
NCT03788174
Fujian Cancer HospitalGastric Adenocarcinoma
Start: 2019-02-01End: 2020-12-31Target: 26Updated: 2019-05-10
Study of the Apatinib Combine With POF Versus POF in Gastric Cancer
NCT04121039
Fujian Cancer HospitalAdvanced Cancer, Gastric Adenocarcinoma
Start: 2019-12-31End: 2023-12-31Target: 116Updated: 2019-10-09
POF Versus FOLFOX Plus IP Paclitaxel in AGC
NCT04155671
Fujian Cancer HospitalGastric Cancer
Start: 2019-12-01End: 2023-06-30Target: 260Updated: 2019-11-07

Phase 3

A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer
NCT03788226
Fujian Cancer HospitalGastric Cancer Stage III
Start: 2019-02-01End: 2023-12-31Target: 600Updated: 2019-10-16

Unknown Phase

PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer
NCT04174339
Fujian Cancer HospitalAdvanced Gastric Adenocarcinoma
Start: 2019-12-10End: 2021-05-02Target: 20Updated: 2019-11-22

Related Papers

Final survival results from a multicenter, randomized phase II trial of intravenous paclitaxel plus FOLFOX (ivPOF) and/or intraperitoneal paclitaxel plus FOLFOX (ipPOF) versus mFOLFOX6 as first-line treatment of advanced gastric cancer (AGC): SYLT/FNF 004.
Journal of Clinical Oncology2021-05-202 citations
POF (paclitaxel/oxaliplatin/5-FU/leucovorin) versus SOX/CAPOX/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer: Study protocol for a randomized controlled trial, FNF-014 trial.
Journal of Clinical Oncology2020-05-20
POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) versus FOLFOX as a first-line treatment in advanced gastric cancer (AGC): Update from a multicenter, randomized phase II trial, FNF-004 trial.
Journal of Clinical Oncology2019-05-2010 citations
FOLFOX versus POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) as a first-line treatment in advanced gastric cancer (AGC): A multicenter, randomized phase II trial, FNF-004 trial.
Journal of Clinical Oncology2019-01-292 citations
A phase II Study of FOLFOX versus POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel) plus FOLFOX as a first-line treatment in advanced gastric cancer (AGC): A feasibility analysis.
Journal of Clinical Oncology2017-02-011 citations